Kelun-Biotech's Sac-TMT Cancer Drug Selected for Three ASCO 2026 Oral Presentations

Key Takeaways

• Three clinical studies of Kelun-Biotech’s sac-TMT cancer drug selected for prestigious ASCO 2026 oral presentations
• Sac-TMT already approved in China for four cancer indications including triple-negative breast cancer and lung cancer
• The drug has received six Breakthrough Therapy Designations from China’s NMPA, indicating significant therapeutic potential

---

Kelun-Biotech Gains Recognition at Premier Cancer Conference

Kelun-Biotech has announced that three clinical studies evaluating its antibody-drug conjugate sac-TMT have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This recognition highlights the growing clinical evidence supporting the drug’s efficacy across multiple cancer types.

Current Market Presence and Approvals

Sac-TMT has already established a strong presence in the Chinese market with four approved indications. The drug is currently marketed for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients who have received at least two prior systemic therapies. Additionally, it’s approved for EGFR mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR-TKI therapy and platinum-based chemotherapy.

Regulatory Recognition and Future Prospects

The National Medical Products Administration (NMPA) has granted sac-TMT six Breakthrough Therapy Designations, underscoring the drug’s potential to address significant unmet medical needs. These designations typically expedite the development and review process for promising therapies.

Clinical Significance

Oral presentations at ASCO represent the highest tier of scientific recognition at the world’s premier cancer conference. The selection of three separate studies suggests robust clinical data across multiple indications and patient populations.

The upcoming presentations will provide the global oncology community with detailed insights into sac-TMT’s clinical performance, potentially influencing treatment guidelines and expanding international market opportunities for Kelun-Biotech.

Market Impact

This development positions Kelun-Biotech as a significant player in the competitive antibody-drug conjugate space, particularly in oncology where innovative treatments command premium pricing and substantial market share.

---

Frequently Asked Questions

What cancers does sac-TMT treat?

Sac-TMT is currently approved in China for triple-negative breast cancer and EGFR mutant-positive non-small cell lung cancer, among other indications, with ongoing studies in additional cancer types.

When will sac-TMT be available outside China?

The timeline for international availability depends on regulatory approvals in other regions. The ASCO presentations may provide data supporting global expansion efforts.

What makes sac-TMT different from other cancer treatments?

Sac-TMT is an antibody-drug conjugate that combines targeted therapy with chemotherapy, potentially offering improved efficacy with reduced side effects compared to traditional chemotherapy alone.